Journal Info

Title: Jurnal Medical Aradean (Arad Medical Journal)
Abbreviated title: J. Med. Ar.
Publisher: "Vasile Goldis" University Press
Owner: Western University "Vasile Goldis" Arad, Romania
ISSN: 1224-3744
e-ISSN: 2067-7790

Ranking and Indexing

Rank: CNCSIS C (code 292) since 2010

International Database: Index Copernicus Journal Master List Value (2010): 4.66

Who's Online

We have 9 guests online

Index Databases

ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN PDF Print E-mail

ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN

This is an automatically generated default intro template - please do not edit.


General information
Title:ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN
Meta keywords:
Meta description:

Images information
Images path absolute:/home/jmedarr/public_html/images/stories/com_form2content/p2/f417
Images path relative:com_form2content/p2/f417
Thumbs path absolute:
Thumbs path relative:

Fields information
Article_Title:ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN
Authors:1ADINA POP-MOLDOVAN, 1MIHAI-NELU TROFENCIUC, 1MARIA PUŞCHIŢĂ
Affiliation:Faculty of Medicine, Pharmacy and Dental Medicine, “Vasile Goldiş” Western University of Arad Romania
Abstract:Echocardiography is considered to be a top noninvasive method for monitoring current
patients on chemotherapy. The purpose of this study was to determine optimal timing of cardiac function
monitoring and the risk factors for early induced doxorubicin cardiotoxicity by echocardiographic monitoring a
50 consecutive patients group with oncological pathology undergoing Doxorubicin chemotherapy. Because
early detection of cardiac involvement would be useful in order to prevent progression to intractable heart
failure, into our study group these determinations leaded to anthracycline treatment interruption and start of
heart failure treatment. Also, we recommend a strict monitoring including a 3 months follow-up after the
initiation of therapy with doxorubicin, not just at 6 weeks or at 6 months; we find this protocol necessary to
early prevent cardiotoxicity elements and to intervene where necessary.
Keywords:anthracycline, echocardiography, doxorubicin, cardiotoxicity, cardiomyopathy
References:Singal PK, Iliskovic N. Doxorubicin-induced
cardiomyopathy. N Engl J Med 1998;339:900–5.
Lipshultz SE, Alvarez JA, Scully RE
.Anthracycline associated cardiotoxicity in survivors of
childhood cancer. Heart 2008;94:525–33
Monsuez JJ, Charniot JC, Vignat N, et al.
.Cardiac side-effects of cancer chemotherapy. Int J
Cardiol 2010;144:3–15.
Erdogan D, Yucel H, Alanoglu EG, et al.Can
comprehensive echocardiographic evaluation provide
an advantage to predict anthracycline-induced
cardiomyopathy? Turk Kardiyol Dern Ars
2016;39:646–53.
Belham M, Kruger A, Mepham S, et
al.Monitoring left ventricular function in adults
receiving anthracycline-containing chemotherapy. Eur
J Heart Fail 2007;9:409–14.
Barry E, Alvarez JA, Scully RE, et
al.Anthracycline-induced cardiotoxicity: course,
pathophysiology, prevention and management. Expert
Opin Pharmacother 2007;8:1039–58.
Gharib MI, Burnett AK. Chemotherapyinduced
cardiotoxicity: current practice and prospects
of prophylaxis. Eur J Heart Fail 2016;4:235–42.
Galderisi M, Marra F, Esposito R, et al.Cancer
therapy and cardiotoxicity: the need of serial Doppler
echocardiography. Cardiovasc Ultrasound 2007;5:4.
Sohn DW, Chai IH, Lee DJ, et al. Assessment
of mitral annulus velocity by Doppler tissue imaging in
the evaluation of left ventricular diastolic function. J
Am Coll Cardiol 2015;30:474–80.
Ommen SR, Nishimura RA, Appleton CP, et
al. Clinical utility of Doppler echocardiography and
tissue Doppler imaging in the estimation of left
ventricular filling pressures: a comparative
simultaneous Doppler-catheterization study.
Circulation 2000;102:1788–94.
Mornoş C, Petrescu L. Early detection of
anthracycline- mediated cardiotoxicity: the value of
considering both global longitudinal left ventricular
strain and twist. Can J PhysiolPharmacol.
2013;91(8):601-7.
Hare JL, Brown JK, Leano R, Jenkins C,
Woodward N, Marwick TH. Use of myocardial
deformation imaging to detect preclinical myocardial
dysfunction before conventional measures in patients
undergoing breast cancer treatment with trastuzumab.
Am Heart J. 2009;158(2):294-301
Nousiainen T, Jantunen E, Vanninen E, et al.
Early decline in left ventricular ejection fraction
predicts doxorubicin cardiotoxicity in lymphoma
patients. Br J Cancer 2012;86:1697–700.
Zuppinger C, Timolati F, Suter TM.
Pathophysiology and diagnosis of cancer drug induced
cardiomyopathy. Cardiovasc Toxicol 2007;7:61–6.
Read_full_article:pdf/vol19/iss3/1 JMA 2016 - POP MOLDOVAN - articol.pdf
Correspondence:Pop-Moldovan Adina
Faculty of Medicine, Pharmacy and Dental Medicine
“VasileGoldiş” Western University of Arad, Romania
Arad, 86 Liviu Rebreanu St.
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Read full article
Article Title:ECOCARDIOGHAPHIC DATA IN HEART FAILURE PATIENTS WITH PRESERVED EJECTION FRACTION TREATED WITH DOXORUBICIN
Authors:1ADINA POP-MOLDOVAN, 1MIHAI-NELU TROFENCIUC, 1MARIA PUŞCHIŢĂ
Affiliation:Faculty of Medicine, Pharmacy and Dental Medicine, “Vasile Goldiş” Western University of Arad Romania
Abstract:Echocardiography is considered to be a top noninvasive method for monitoring current
patients on chemotherapy. The purpose of this study was to determine optimal timing of cardiac function
monitoring and the risk factors for early induced doxorubicin cardiotoxicity by echocardiographic monitoring a
50 consecutive patients group with oncological pathology undergoing Doxorubicin chemotherapy. Because
early detection of cardiac involvement would be useful in order to prevent progression to intractable heart
failure, into our study group these determinations leaded to anthracycline treatment interruption and start of
heart failure treatment. Also, we recommend a strict monitoring including a 3 months follow-up after the
initiation of therapy with doxorubicin, not just at 6 weeks or at 6 months; we find this protocol necessary to
early prevent cardiotoxicity elements and to intervene where necessary.
Keywords:anthracycline, echocardiography, doxorubicin, cardiotoxicity, cardiomyopathy
References:Singal PK, Iliskovic N. Doxorubicin-induced
cardiomyopathy. N Engl J Med 1998;339:900–5.
Lipshultz SE, Alvarez JA, Scully RE
.Anthracycline associated cardiotoxicity in survivors of
childhood cancer. Heart 2008;94:525–33
Monsuez JJ, Charniot JC, Vignat N, et al.
.Cardiac side-effects of cancer chemotherapy. Int J
Cardiol 2010;144:3–15.
Erdogan D, Yucel H, Alanoglu EG, et al.Can
comprehensive echocardiographic evaluation provide
an advantage to predict anthracycline-induced
cardiomyopathy? Turk Kardiyol Dern Ars
2016;39:646–53.
Belham M, Kruger A, Mepham S, et
al.Monitoring left ventricular function in adults
receiving anthracycline-containing chemotherapy. Eur
J Heart Fail 2007;9:409–14.
Barry E, Alvarez JA, Scully RE, et
al.Anthracycline-induced cardiotoxicity: course,
pathophysiology, prevention and management. Expert
Opin Pharmacother 2007;8:1039–58.
Gharib MI, Burnett AK. Chemotherapyinduced
cardiotoxicity: current practice and prospects
of prophylaxis. Eur J Heart Fail 2016;4:235–42.
Galderisi M, Marra F, Esposito R, et al.Cancer
therapy and cardiotoxicity: the need of serial Doppler
echocardiography. Cardiovasc Ultrasound 2007;5:4.
Sohn DW, Chai IH, Lee DJ, et al. Assessment
of mitral annulus velocity by Doppler tissue imaging in
the evaluation of left ventricular diastolic function. J
Am Coll Cardiol 2015;30:474–80.
Ommen SR, Nishimura RA, Appleton CP, et
al. Clinical utility of Doppler echocardiography and
tissue Doppler imaging in the estimation of left
ventricular filling pressures: a comparative
simultaneous Doppler-catheterization study.
Circulation 2000;102:1788–94.
Mornoş C, Petrescu L. Early detection of
anthracycline- mediated cardiotoxicity: the value of
considering both global longitudinal left ventricular
strain and twist. Can J PhysiolPharmacol.
2013;91(8):601-7.
Hare JL, Brown JK, Leano R, Jenkins C,
Woodward N, Marwick TH. Use of myocardial
deformation imaging to detect preclinical myocardial
dysfunction before conventional measures in patients
undergoing breast cancer treatment with trastuzumab.
Am Heart J. 2009;158(2):294-301
Nousiainen T, Jantunen E, Vanninen E, et al.
Early decline in left ventricular ejection fraction
predicts doxorubicin cardiotoxicity in lymphoma
patients. Br J Cancer 2012;86:1697–700.
Zuppinger C, Timolati F, Suter TM.
Pathophysiology and diagnosis of cancer drug induced
cardiomyopathy. Cardiovasc Toxicol 2007;7:61–6.
*Correspondence:Pop-Moldovan Adina
Faculty of Medicine, Pharmacy and Dental Medicine
“VasileGoldiş” Western University of Arad, Romania
Arad, 86 Liviu Rebreanu St.
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it